Edition:
United Kingdom

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

12.53USD
3:56pm GMT
Change (% chg)

$0.18 (+1.46%)
Prev Close
$12.35
Open
$12.29
Day's High
$12.78
Day's Low
$12.20
Volume
133,670
Avg. Vol
788,806
52-wk High
$14.47
52-wk Low
$3.30

Chart for

About

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $1,461.92
Shares Outstanding(Mil.): 125.38
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Immunomedics appoints Michael Pehl president and CEO

* Immunomedics appoints Michael Pehl president and chief executive officer to lead next phase of transformative growth

09 Nov 2017

BRIEF-Immunomedics announces first quarter fiscal results

* Immunomedics announces first quarter fiscal 2018 results and provides corporate update

09 Nov 2017

BRIEF-Immunomedics to exchange about $80 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock

* Immunomedics announces agreements to exchange approximately $80.0 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock

15 Sep 2017

BRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (i

* Immunomedics presents interim phase 2 results with sacituzumab govitecan (immu-132) in patients with pretreated metastatic urothelial cancer Source text for Eikon: Further company coverage:

11 Sep 2017

BRIEF-Immunomedics announces publication of cancer drug data

* Immunomedics announces publication of phase 2 results with labetuzumab govitecan (immu-130) that demonstrate promising efficacy as a single agent in patients with metastatic colorectal cancer

21 Aug 2017

BRIEF-Immunomedics reports Q4 loss per share $0.48

* Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline

16 Aug 2017

BRIEF-Immunomedics files for offering of 34.8 mln shares of common stock by selling stockholders

* Immunomedics files for offering of 34.8 million shares of common stock by selling stockholders - sec filing

31 Jul 2017

BRIEF-Immunomedics files for 34.8 mln shares of co's common stock

* Files for 34.8 million shares of co's common stock by the selling stockholders - sec filing

31 Jul 2017

BRIEF-Seattle Genetics reports 8.2 percent stake in Immunomedics as of June 29, 2017

* Seattle genetics inc reports a 8.2 percent stake in immunomedics inc as of June 29, 2017 - sec filing

07 Jul 2017

Competitors

Earnings vs. Estimates